trending Market Intelligence /marketintelligence/en/news-insights/trending/4hzshp6n0izvzsczzu0ylg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

India's Zydus Healthcare acquires six drug brands from Merck

Power Forecast Briefing: Tight Reserves to Benefit Conventional Gas Generation versus Renewable Energy

Mining Exploration Insights

State of the Market: Mining Q2-2019

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency


India's Zydus Healthcare acquires six drug brands from Merck

India's Zydus Healthcare Ltd. acquired six brands from Merck & Co. Inc. that fall under the categories of men's health, women's health, wound management and cardiovascular therapy.

The brands are Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten, which had sales of 840 million Indian rupees in 2015.

The companies did not disclose the financial terms of the acquisition.

As of Dec. 28, US$1 was equivalent to 68.21 Indian rupees.